StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a report published on Friday. The firm issued a sell rating on the medical device company’s stock.
NeuroMetrix Trading Up 0.7 %
NASDAQ:NURO opened at $4.44 on Friday. NeuroMetrix has a twelve month low of $2.70 and a twelve month high of $11.55. The stock has a fifty day simple moving average of $3.89 and a 200-day simple moving average of $3.76.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last released its earnings results on Thursday, February 22nd. The medical device company reported ($1.43) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 31.31% and a negative net margin of 110.64%. The business had revenue of $1.32 million for the quarter.
Institutional Trading of NeuroMetrix
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Read More
- Five stocks we like better than NeuroMetrix
- What Makes a Stock a Good Dividend Stock?
- Snap Crackles and Pops on Surprise Profit and Raised Guidance
- Buy P&G Now, Before It Sets A New All-Time High
- MarketBeat Week in Review – 4/22 – 4/26
- The “How” and “Why” of Investing in 5G Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.